• Affiliate Professor, Global Health
  • Founder & CEO, HDT Bio Corp.
Steven Reed

1616 Eastlake Avenue E #280
Seattle, WA 98102
United States

Select from the following:

Steve Reed is the co-founder, President, and CEO of HDT Bio, based in Seattle, USA. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College Research Professor of Pathobiology at the University of Washington. Dr. Reed received a PhD in Microbiology and Immunology from the University of Montana in 1979. That year he was appointed as Scientist of the National Institute of Amazon Research in Manaus, Brazil, where he directed research on tropical diseases.
Dr. Reed joined Cornell University Medical College in 1980 as Assistant Professor of Medicine, continuing to work in Brazil as manager of the Cornell-Bahia program in International Medicine. He joined the Seattle Biomedical Research Institute in 1984 where he worked until founding the Infectious Disease Research Institute (IDRI) in 1993 when he served in various capacities until 2019. He has received over $140 million in grants from the NIH, BARDA, DARPA, and Gates Foundation. In 1994 he co-founded Corixa Corporation (which was later sold to GlaxoSmithKline, GSK) where he served as Chief Scientific Officer until leaving in 2004. In 2008 Dr. Reed, together with Rick Klausner, David Baltimore, and Ralph Steinman founded Immune Design Corp. (IMDZ, NASDAQ), a cancer therapeutics company, where he served as CEO until 2011. In 2014 he co-founded Afrigen Biologics in Cape Town, where he served as Director until 2019.
Dr. Reed’s research interests have focused on the immunology of intracellular infections, and on the development of vaccines and diagnostics for both cancer and infectious diseases. In partnership with GSK, he led the team that developed the first defined tuberculosis vaccine, now in advanced clinical development. He also developed the first defined vaccines for leishmaniasis and leprosy, as well as the K39-based diagnostic tests currently licensed for leishmaniasis. He has more than 400 original publications, 36 book chapters and reviews, and 109 issued patents on diagnostics, vaccines, and therapeutics of adjuvants, cancer, and infectious diseases.

  • PhD (University of Montana)
  • MS (University of Montana)
  • BA (Whitman College)
Country Affiliations 
  • Portuguese
Health Topics 
  • Biodefense Infectious Diseases
  • Cancer
  • Cervical Cancer
  • Drug and Vaccine Development
  • Infectious Diseases (other than STDs)
  • Influenza
  • Innate Immunity
  • Leishmaniasis
  • Molecular Immunology
  • Neglected Diseases, Tropical Medicine (incl. Parasites)
  • Pathobiology
  • Research
  • TB
  • Viruses
  • Zoonotic Diseases and Animal Health
Pathobiology research areas 
DGH Centers, Programs and Initiatives and Affiliated Organizations 

Immunological response to mycobacteria infections


Innovative tools and approaches to end the transmission of Mycobacterium leprae. Steinmann P, Reed SG, Mirza F, Hollingsworth TD, Richardus JH. Lancet Infect Dis. 2017 Jul 7. pii: S1473-3099(17)30314-6. doi: 10.1016/S1473-3099(17)30314-6. [Epub ahead of print] Review.PMID: 28693856

CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination. Christiaansen AF, Dixit UG, Coler RN, Marie Beckmann A, Reed SG, Winokur PL, Zimmerman MB, Varga SM, Wilson ME.Vaccine. 2017 Jul 24;35(33):4255-4261. doi: 10.1016/j.vaccine.2017.06.013. Epub 2017 Jun 27. PMID: 28662951

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, Shen X, Parks R, Goodman D, Eaton A, Balachandran H, Mach LV, Saunders KO, Weiner JA, Scearce R, Sutherland LL, Phogat S, Tartaglia J, Reed SG, Hu SL, Theis JF, Pinter A, Montefiori DC, Kepler TB, Peachman KK, Rao M, Michael NL, Suscovich TJ, Alter G, Ackerman ME, Moody MA, Liao HX, Tomaras G, Ferrari G, Korber BT, Haynes BF. Nat Commun. 2017 Jun 8;8:15711. doi: 10.1038/ncomms15711. PMID: 28593989

Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis. Duthie MS, Reed SG. Clin Vaccine Immunol. 2017 Jul 5;24(7). pii: e00108-17. doi: 10.1128/CVI.00108-17. Print 2017 Jul. Review. PMID: 28515135

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines. Van Hoeven N, Fox CB, Granger B, Evers T, Joshi SW, Nana GI, Evans SC, Lin S, Liang H, Liang L, Nakajima R, Felgner PL, Bowen RA, Marlenee N, Hartwig A, Baldwin SL, Coler RN, Tomai M, Elvecrog J, Reed SG, Carter D. Sci Rep. 2017 Apr 21;7:46426. doi: 10.1038/srep46426. PMID: 28429728